LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed (HCC)

This study has been completed.
Biocompatibles UK Ltd
Information provided by (Responsible Party):
David Geller, MD, University of Pittsburgh Identifier:
First received: April 4, 2009
Last updated: January 5, 2016
Last verified: January 2016
Advanced HCC represents a high unmet medical need with a poor prognosis and few therapeutic options. Patients who present with HCC beyond the currently accepted Milan criteria are not eligible to be listed for liver transplantation. The proposed study offers local regional therapy to a defined population of patients beyond Milan criteria as an attempt to downstage them to eligibility for liver transplant.

Condition Intervention Phase
Hepatocellular Carcinoma
Drug: LC Bead loaded with doxorubicin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: LC Drug Eluting Bead for Regional Chemoembolization to Downstage Unresectable Hepatocellular Carcinoma (HCC) to Liver Transplantation

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Determine the number of patients in the cohort effectively downstaged to transplant eligibility with the LC BeadTM [ Time Frame: 36 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine the objective tumor response rate in patients with HCC treated with LC BeadTM using EASL and RECIST criteria [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Determine the symptomatic and quality-of-life measures in patients treated with the LC BeadTM [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Determine the local effects of the LC BeadTM in the explanted liver of those patients who go on to receive liver transplantation [ Time Frame: 36 months ] [ Designated as safety issue: No ]

Enrollment: 1
Study Start Date: November 2008
Study Completion Date: April 2012
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LC Drug Eluting Bead, Regional Chemoembolization
Use of LC Drug-Eluting Beads for chemoembolization will provide a method for downstaging patients with hepatocellular carcinoma which is not amenable to surgical resection or local ablative therapy to liver transplant eligibility
Drug: LC Bead loaded with doxorubicin
LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
Other Name: LC Bead

Detailed Description:

LC BeadTM is a new product specifically designed for TACE. LC BeadTM microspheres can be loaded with doxorubicin (Trade name: adriamycin), a chemotherapeutic anthracycline glycolide agent widely accepted for treatment of HCC. This novel bead slowly releases the ionically bound chemotherapeutic agent rather than administering a bolus of chemotherapy as is the case with many alternative methods of TACE. Thus, the LC BeadTM offers the potential advantage of less toxicity and prolonged tumor exposure.

This study offers local regional therapy to a defined population of patients beyond transplant criteria as an attempt to downstage them to eligibility for liver transplantation. This study will make an important contribution to understanding the beads' local effect as seen in the explanted livers of those patients who go on to receive a liver transplant. Additionally, we will examine the impact of this novel treatment tool on patients' quality of life.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
  • Adults patients (≥ 18 years of age) with a diagnosis of HCC that is not amenable to surgical resection or local ablative therapy
  • Histological confirmed HCC or clinical/laboratory diagnosis of HCC or nodules larger than 2cm with typical vascular features or AFP > 200
  • Patient must have one lesion < 8cm or up to five lesions with total diameter < 8cm
  • Quantifiable disease limited to the liver; 40% of liver must be free of tumor burden
  • Patient must have at least one tumor lesion that meets both of the following criteria:

    • Lesion can be accurately measured in at least one dimension according to RECIST criteria
    • Lesion has not been previously treated with surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation.
  • ECOG performance status ≤ 2
  • No prior systemic chemotherapy
  • At least 4 weeks since prior TACE or interferon
  • Not pregnant
  • No significant baseline liver dysfunction. Child-Pugh class A and B 7-8 (in abscence of ascites)
  • No significant renal impairment (creatinine clearance < 30mL/minute) or patients on dialysis
  • No current infections requiring antibiotic therapy
  • Not on anticoagulation or suffering from a known bleeding disorder
  • No unstable coronary artery disease or recent MI
  • The following laboratory parameters

    • Hemoglobin ≥ 8.5g/dL
    • Total bilirubin ≤ 3.0mg/dL
    • ALT and AST ≤ 5x upper limit of normal
    • Serum creatinine ≤ 1.5x upper limit of normal
    • INR ≤ 1.5 or a PT/PTT within normal limits
    • Platelet count ≥ 50,000/uL
  • Ability to understand the protocol and to agree to and sign a written informed consent document

Exclusion Criteria:

  • HCC with gross vascular invasion or extrahepatic disease
  • Previous or concurrent cancer that is distinct in primary site or histology from HCC except cervical carcinoma in situ, treated basal-cell carcinoma of the skin, superficial bladder tumors (Ta, Tis & T1), and any cancer curatively treated > 3 years prior to entry is permitted
  • Renal failure requiring dialysis
  • Child-Pugh B9 or C hepatic impairment
  • History of cardiac disease: NYHA class 2 congestive heart failure, active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, and uncontrolled hypertension. Myocardial infarction more than 6 months prior to study entry is permitted.
  • Active clinically serious infections (> CTCAEv3 grade 2)
  • Known history of HIV
  • Known central nervous system tumors including metastatic brain disease
  • History of organ allograft
  • Substance abuse (current), psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  • Allergy to the investigational agents or any agent given in association with this trial.
  • Pregnant or breast-feeding patients. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.
  • Uncontrolled hypertension defined as systolic blood pressure > 150mmHg or diastolic blood pressure > 90mmHg
  • Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
  • Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug
  • Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug
  • Serious non-healing wound, ulcer, or bone fracture
  • Any contraindication for doxorubicin administration:

    • serum bilirubin > 3mg/dL
    • WBC < 3000 cells/mm3
    • neutrophil < 1500 cells/mm3
    • cardiac ejection fraction < 50 percent assessed by isotopic ventriculography, echocardiography or MRI
    • MUGA scan < 40% ejection fraction
  • Any contraindication for hepatic embolization procedures

Excluded therapies and medications, previous and concomitant:

  • Prior use of any systemic anti-cancer chemotherapy for HCC
  • Prior use of any systemic investigational agents for HCC
  • Major surgery within 6 weeks of start of study drug
  • Radiotherapy during study or within 3 weeks prior to start of study drug
  • Use of biological response modifiers such as granulocyte colony-stimulating factor (G-CSF)within 3 weeks prio to study entry
  • Autologous bone marrow transplant or stem cell rescue within four months of study drug initiation
  • Concomitant treatment with rifampin or St. John's wort
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00877071

United States, Pennsylvania
UPMC Liver Cancer Center, Montefiore 7 South, 3459 Fifth Avenue
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Biocompatibles UK Ltd
Principal Investigator: David A Geller, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: David Geller, MD, David Geller, PI, University of Pittsburgh Identifier: NCT00877071     History of Changes
Other Study ID Numbers: PRO08070016 
Study First Received: April 4, 2009
Last Updated: January 5, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Liver Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on February 04, 2016